Moderna (MRNA) EBITDA Margin (2017 - 2026)
Moderna's (MRNA) quarterly EBITDA Margin came in at 562.07% in Q2 2026, up 7666.0% year-over-year from 7.24% in Q2 2025, and down 57.53% quarter-over-quarter from 356.81% in Q1 2026.
Powered by 
Analysis
Moderna (MRNA) EBITDA Margin (2017 - 2026) Analysis & Trends
Moderna (MRNA) has reported EBITDA Margin for 10 consecutive years, with 562.07% the latest figure, recorded in Q2 2026.
- On a quarterly basis, EBITDA Margin rose 7666.0% year-over-year to 562.07% in Q2 2026; TTM through Jun 2026 was 149.01%, a 4268.0% decrease from a year earlier, with the FY2025 full-year figure at 158.13%, down 3622.0% from the prior year.
- EBITDA Margin was 562.07% for Q2 2026 at Moderna, down from 356.81% in the prior quarter.
- Over five years, EBITDA Margin peaked at 69.68% in Q1 2022 and troughed at 972.22% in Q1 2025.
- A 5-year average of 256.85% and a median of 118.14% in 2023 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin plunged 73843 bps in 2024 and soared 61541 bps in 2026, its largest moves.
- Over 5 years, EBITDA Margin stood at 31.08% in 2022, then slumped by 99 bps to 0.21% in 2023, then slumped by 60530 bps to 128.99% in 2024, then advanced by 2 bps to 126.4% in 2025, then tumbled by 345 bps to 562.07% in 2026.
- The last three EBITDA Margin figures came in at 562.07% (Q2 2026), 356.81% (Q1 2026), and 126.4% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -25,380.93% |
| 10 | Insmed | 27.67 Bn | 26.51 Bn | 358.27 Mn | -0.36% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -562.07% |
| Mar 31, 2026 | -356.81% |
| Dec 31, 2025 | -126.40% |
| Sep 30, 2025 | -25.59% |
| Jun 30, 2025 | -638.73% |
| Mar 31, 2025 | -972.22% |
| Dec 31, 2024 | -128.99% |
| Sep 30, 2024 | -3.76% |
| Jun 30, 2024 | -565.56% |
| Mar 31, 2024 | -758.08% |
| Dec 31, 2023 | 0.21% |
| Sep 30, 2023 | -109.89% |
| Jun 30, 2023 | -542.73% |
| Mar 31, 2023 | -19.66% |
| Dec 31, 2022 | 31.08% |
| Sep 30, 2022 | 34.66% |
| Jun 30, 2022 | 51.53% |
| Mar 31, 2022 | 69.68% |
| Dec 31, 2021 | 75.02% |
| Sep 30, 2021 | 71.60% |